Financial Comparison Highlights Revenue and Margin Differences Between GRAIL and Guardant…
What happened
A comparison of GRAIL and Guardant Health showed that Guardant Health produced $1.18 billion in trailing revenue, compared to $165.26 million for GRAIL. Guardant Health reported a gross margin of 65.01%, while GRAIL's was 49.71%. Guardant Health's revenue growth was 44.30%, outpacing GRAIL's 25.70%.
From insidermonkey.com
Why it matters
The comparison highlights a significant difference in commercial scale, noting that Guardant Health's revenue is seven times that of GRAIL. While both companies operate in cancer detection, the financial metrics indicate different stages of commercial maturity and operational efficiency between the two firms.
From insidermonkey.com
Who's involved
- GRAILAmerican biotechnology company competing in cancer detection blood tests
- Guardant HealthAmerican biotechnology company competing in cancer detection blood tests
- NasdaqStock exchange where Guardant Health is publicly traded
Who could feel it
Possible knock-on effectsThese are possibilities Brind reasoned out, not predictions, and not advice. Most are not stated in any report.
- GRAILSpeculative
GRAIL might face pressure on its funding or sales due to its lower revenue and severe operating losses compared to Guardant Health.
Keep exploring
The entities involved
-
GRAIL
American biotechnology and pharmaceutical company
Nothing else this week.
-
Guardant Health
American biotechnology company
Nothing else this week.